title: Antifungal antibiotics and breakthrough bacteremias.
abstract: Patients with fever and neutropenia are at high risk for infection ( approximately 50%) and bacteremia ( approximately 20%). As a result, most are treated with antibacterial prophylaxis until their absolute neutrophil count exceeds 500 cells/mm(3) and their temperature returns to normal. The 1997 guidelines of the Infectious Diseases Society of America suggested 1 of 3 regimens: vancomycin plus ceftazidime, monotherapy with ceftazidime or imipenem (possibly cefepime or meropenem), or dual therapy with an aminoglycoside plus an antipseudomonal beta-lactam.
authors.affiliation: Department of 1Internal Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298-0663, USA. rwenzel@hsc.vcu.edu
authors.forename: R P
authors.initials: RP
authors.lastname: Wenzel
authors.forename: C
authors.initials: C
authors.lastname: Gennings
authors.forename: M B
authors.initials: MB
authors.lastname: Edmond
mesh_terms: D019072:Antibiotic Prophylaxis / Q000706:statistics & numerical data*; D000935:Antifungal Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000453:epidemiology*; D005334:Fever / Q000150:complications*; D006801:Humans; D009181:Mycoses / Q000517:prevention & control*; D009503:Neutropenia / Q000150:complications*
chemical_list: D000935:Antifungal Agents